Chunjian Liu
Bristol-Myers Squibb (United States)(US)
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Monoclonal and Polyclonal Antibodies Research, Galectins and Cancer Biology, Biochemical and Molecular Research, Synthesis and Biological Evaluation
Most-Cited Works
- → Selective Itk Inhibitors Block T-Cell Activation and Murine Lung Inflammation(2004)112 cited
- → Discovery of 2-amino-heteroaryl-benzothiazole-6-anilides as potent p56lck inhibitors(2003)106 cited
- → Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2(2020)81 cited
- → Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors(2006)75 cited
- → 5-Cyanopyrimidine Derivatives as a Novel Class of Potent, Selective, and Orally Active Inhibitors of p38α MAP Kinase(2005)70 cited
- → Discovery of 4-(5-(Cyclopropylcarbamoyl)-2-methylphenylamino)-5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a Clinical p38α MAP Kinase Inhibitor for the Treatment of Inflammatory Diseases(2010)57 cited
- → Benzothiazole based inhibitors of p38α MAP kinase(2008)51 cited
- → Identification of Imidazo[1,2-b]pyridazine Derivatives as Potent, Selective, and Orally Active Tyk2 JH2 Inhibitors(2019)49 cited
- → Discovery of N-[2-[2-[[3-Methoxy-4-(5-oxazolyl)phenyl]amino]-5-oxazolyl]phenyl]-N-methyl-4- morpholineacetamide as a Novel and Potent Inhibitor of Inosine Monophosphate Dehydrogenase with Excellent in Vivo Activity(2002)41 cited
- → Purine derivatives as potent Bruton’s tyrosine kinase (BTK) inhibitors for autoimmune diseases(2014)39 cited